Table 3.
The systemic use of antibiotics against MDR-GNB in two groups (n (%))
| Groups | Carbapenem* | β-lactam/β-lactamase inhibitor† | Fluoroquinolone‡ | Cephalosporin§ | Total (N) | P|| |
|---|---|---|---|---|---|---|
| Amikacin group | 17 (37) | 9 (20) | 14 (30) | 6 (13) | 46 | 0.6202 |
| Placebo group | 14 (35) | 5 (13) | 12 (30) | 9 (23) | 40 |
*Meropenem or imipenem; †Piperacillin/tazobactam or cefoperazone/sulbactam; ‡Moxifloxacin, ciprofloxacin, or levofloxacin; §Ceftazidime, ceftriaxone, or cefoselis; ||Pearson Chi-square test, χ2 = 1.776. MDR-GNB: Multidrug-resistant Gram-negative bacteria.